| Abstract: | Novel benzoheterocyclic compounds of the formula: wherein R1 is H, halogen, alkyl, optionally substituted amino, alkoxy; R2 is H, halogen, alkoxy, phenylalkoxy, OH, alkyl, optionally substituted amino, carbamoyl-alkoxy, optionally substituted amino-alkoxy, optionally substituted benzoyloxy; R3 is a group: -NR4R5 or -CO-NR11R12; R4 is H, optionally substituted benzoyl, alkyl; R5 is a group: [R16 is halogen, optionally substituted alkyl, OH, alkoxy, alkanoyloxy, alkylthio, alkanoyl, carboxy, alkoxycarbonyl, CN, NO2, optionally substituted amino, phenyl, cycloalkyl, etc., or a group: -O-A-NR6R7; m is 0 to 3], phenyl-alkoxycarbonyl, alkanoyl, phenylalkanoyl, etc.; R11 is H or alkyl; R12 is cycloalkyl or optionally substituted phenyl; and W is a group: -(CH2)p (p is 3 to 5) or -CH=CH-(CH2)q (q is 1 to 3), the carbon atom of these groups begin optionally replaced by O, S, SO, SO2 or a group: -N(R13)- and further these groups having optionally 1 to 3 substituents of alkyl, alkoxycarbonyl, carboxy, OH, O, alkanoyloxy, etc., which have excellent vasopressin antagonistic activities and are useful as vasodilator, hypotensive agent, water diuretics, platelet agglutination inhibitor, and a vasopressin antagonistic composition containing the compound as the active ingredient. |
| Inventor(s): | Hidenori Ogawa, Hisashi Miyamoto, Kazumi Kondo, Hiroshi Yamashita, Kenji Nakaya, Hajime Komatsu, Michinori Tanaka, Shinya Kora, Michiaki Tominaga, Yoichi Yabuuchi |
|
Patent landscape, scope, and claims: |
United States Patent 5,258,510: Scope, Claims, and Patent-Landscape Readout
No substantive claim or scope analysis is possible from the information provided. The prompt includes only: “The claims are:” without the actual claim text, claim numbers, or any excerpted portions of the patent document.
What is missing for claim-scope analysis
A complete and accurate scope and landscape readout requires the patent’s operative content, including:
- Full independent claim(s) (with all limitations)
- Full dependent claim set (or at least representative dependent claims)
- The patent’s specification-derived definitions and embodiments that bound interpretation
- Priority/continuity data (filing date, priority date, and any CIP/continuation chain)
- Legal status and prosecution history signals that constrain claim construction (e.g., cancellations, amendments, final allowed wording)
What can be produced from the patent number alone (without claims/spec)
A patent number alone does not support:
- Claim construction
- Literal scope boundaries
- Design-around risk mapping
- Strength scoring by limitation coverage
- Freedom-to-operate style relevance across competing assets
Because the operative claim text is not present, any “detailed analysis” would require invention, which is not acceptable for a patent-landscape decision process.
Key Takeaways
- A detailed scope and claims analysis for US 5,258,510 cannot be generated from the provided input.
- No patent-landscape conclusions can be responsibly derived without the actual claim language and related document content.
FAQs
-
Can you analyze claim scope using only “United States Drug Patent 5,258,510” without claim text?
No. Scope analysis depends on the specific limitations in the allowed claims and their construction.
-
Is the patent number enough to map the landscape?
Not in a decision-grade way. Landscape mapping needs claim themes (what is claimed) to find close variants and likely design-arounds.
-
Would a high-level summary still be reliable?
It would not meet a strict claim-scope requirement because “drug patent” covers multiple possible subject matters and claim structures.
-
Can you extract claims from public records based only on the number?
Not from the current prompt content. The assistant has not been given the claim text or document extracts needed for an analysis.
-
What would make the analysis complete?
The full operative claim set (independent and dependent claims) and enough specification excerpt to support key term definitions.
References
[1] None provided in the prompt.
More… ↓
⤷ Start Trial
|
